glp-1 stock market Receptor Agonist Size, Share GLP-1 Receptor Agonist Market Size

Front Immunol 13:971048

However, those who quit the medications for six months saw a slightly higher risk, and those who stopped for two years had saw their risk rise 22%

14,15 Potential Direct Effects on the Heart Although the systemic indirect effects of GLP-1RAs are well established as the primary drivers of their clinical benefit in HF, emerging preclinical and mechanistic evidence suggests GLP-1RAs may also exert some direct cardioprotective effects, as discussed below

The question is whether that system is being supported well

Scientists originally created these medications for patients with type 2 diabetes, but the US Food and Drug Administration (FDA) has also approved them for weight loss in certain people